| Tausif Butt |
Currently, Tausif Butt holds the position of Chief Operating Officer & Executive Vice President for ChemoCentryx, Inc.
In his past career Mr. Butt occupied the position of Senior Vice President-Latin America at AstraZeneca Plc.
Mr. Butt received an undergraduate degree from the University of Brighton and a graduate degree from Imperial College London. |
| David M. Reese |
David M. Reese was the founder of Translational Oncology Research International, Inc. (founded in 2003) where he served as President & Chief Medical Officer from 2003 to 2005. He currently holds the position of Chief Executive Officer at Onyx Pharmaceuticals, Inc., KAI Pharmaceuticals, Inc., Five Prime Therapeutics, Inc., ChemoCentryx, Inc., Alantos Pharmaceuticals Holding, Inc., BioVex Group, Inc., and Director at CEO Roundtable on Cancer, Inc. He is also a Director at Research!America since 2023. Previously, he worked as Director-Clinical Research at Translational Research In Oncology and Breast Cancer International Research Group Ltd. He holds an undergraduate degree from The University of Cincinnati College of Medicine and Harvard College. |
| Rita I. Jain |
Currently, Rita I. Jain occupies the position of Chief Medical Officer, Executive Director & EVP at ChemoCentryx, Inc. Dr. Jain is also on the board of AM-Pharma Holding BV and AM-Pharma BV.
In her past career she occupied the position of Chief Medical Officer & Senior Vice President for Akebia Therapeutics, Inc., Vice President-Pharmaceutical Development at Abbott Laboratories, Vice President-Health & Metabolic Development at AbbVie, Inc., Chief Medical Officer & Senior Vice President of Immunovant, Inc., Member of North Shore University Hospital and Assistant Professor at New York University School of Medicine.
Dr. Jain received an undergraduate degree from Long Island University and a doctorate from Stony Brook University School of Medicine. |
| Thomas J. Schall |
Founder of ChemoCentryx, Inc., Thomas J. Schall is Chairman, President & Chief Executive Officer at this company.
Dr. Schall previously held the position of Scientist at Genentech, Inc. and Principal at DNAX Research Institute of Molecular & Cellular Biology, Inc.
Dr. Schall received a doctorate from Stanford University and an undergraduate degree from Northern Illinois University. |
| Ching Yau Yi |
Ching Yau Yi is currently the Chief Accounting Officer & Senior VP-Finance at ChemoCentryx, Inc. Prior to this, she was the Chief Accounting Officer at BridgeBio Pharma, Inc. from 2019 to 2022. She also worked as the Vice President-Finance at Nektar Therapeutics from 2018 to 2019 and as a Controller at Theravance Biopharma, Inc. from 2013 to 2018. Ms. Yi's former experience also includes working as a Senior Manager at Ernst & Young LLP from 2003 to 2013. She received her undergraduate degree from Nanyang Technological University in 1999. |
| Susan M. Kanaya |
Susan M. Kanaya is Chief Financial Officer, Secretary & Director at ChemoCentryx, Inc.
In her past career she occupied the position of Controller for 50, Chief Financial Officer & Senior VP-Finance at Kosan Biosciences, Inc., Treasurer & Vice President-Finance at Sugen, Inc. and Controller of KPMG, Inc.
She received an undergraduate degree from the University of California, Berkeley. |
| Sangita Ghosh |
Sangita Ghosh is a professional who has worked in various pharmaceutical companies. She is currently the Senior Vice President-Technical Operations at ChemoCentryx, Inc. Prior to this, she worked as the Vice President-Pharmaceutical Development at Adamas Pharmaceuticals LLC from 2012 to 2018 and as the VP-Pharmaceutical Development & Manufacturing at Spruce Biosciences, Inc. from 2018 to 2020. She also worked as a Senior Director at Transcept Pharma, Inc. She holds a doctorate degree from the Indian Institute of Science and a graduate degree from the Indian Institute of Technology Kanpur. |
| Jennifer L. Herron |
Jennifer L. Herron is on the board of ChemoCentryx, Inc., Genocea Biosciences, Inc. and Gwynedd-Mercy Academy and Chief Commercial Officer & Senior Vice President at ADC Therapeutics SA.
In her past career Ms. Herron was President & Executive VP-Global Commercial at MorphoSys AG, Vice President-US Immunology at Bristol Myers Squibb Co., Chief Commercial Office & Executive Vice President at ImmunoGen, Inc., Chief Commercial Officer & Executive VP of ARIAD Pharmaceuticals, Inc., Associate for Boehringer Mannheim Pharmaceuticals Corp. and President & EVP-Global Commercial at Bio-Rad AbD Serotec, Inc.
Ms. Herron received an undergraduate degree from Lehigh University and an MBA from Georgetown University. |
| David E. Wheadon |
David E. Wheadon is Member of American Academy of Pharmaceutical Physicians and on the board of 6 other companies.
In his past career Dr. Wheadon occupied the position of Director-Clinical Research at Smithkline Beecham Pharmaceuticals Ltd., Executive Vice President-Research & Advocacy at Juvenile Diabetes Research Foundation, Senior VP-Global Pharmaceutical Regulatory at Abbott Laboratories, Senior Vice President-US Regulatory Affairs at GSK Plc, Senior Vice President-Global Regulatory Affairs at AstraZeneca Plc and SVP-Global Regulatory Affairs & Patient Safety at AstraZeneca Pharmaceuticals LP (a subsidiary of AstraZeneca Plc), Executive Vice President-Research & Advocacy at JDRF International and Senior VP-Scientific & Regulatory Affairs at Pharmaceutical Research & Manufacturers of America.
David E. Wheadon received a doctorate from The Johns Hopkins University School of Medicine and an undergraduate degree from Harvard College. |
| Geoffrey M. Parker |
Presently, Geoffrey M. Parker holds the position of Chief Operating & Financial Officer, Executive VP at Tricida, Inc. He is also on the board of ChemoCentryx, Inc., Perrigo Co. Plc, Better Therapeutics LLC and Better Therapeutics, Inc.
In his past career Mr. Parker occupied the position of Chief Financial Officer & Senior Vice President of Anacor, Inc., Partner at The Goldman Sachs Group, Inc., Vice President of Feibusch & Co., Inc., Chief Financial Officer & Executive Vice President for Anacor Pharmaceuticals, Inc. and Chief Business Officer at InteKrin Therapeutics, Inc.
Geoffrey M. Parker received an undergraduate degree from Dartmouth College and an MBA from Stanford Graduate School of Business. |
| Thomas A. Edwards |
Thomas A. Edwards is on the board of ChemoCentryx, Inc. and Member of The State Bar of California.
Mr. Edwards received an undergraduate degree from Harvard College and a graduate degree from Harvard Law School. |
| James L. Tyree |
James L. Tyree founded Tyree & D'Angelo Partners LLC. Presently, Mr. Tyree is Chairman & Managing Partner at this company. Mr. Tyree is also on the board of ChemoCentryx, Inc., Genelux Corp. (former Chairman) and Assertio Holdings, Inc. and Member of The Chicago Council on Global Affairs.
In the past Mr. Tyree occupied the position of Executive Vice President-Pharmaceutical Products at Abbott Laboratories and President of Abbott Biotech Ventures, Inc. (a subsidiary of Abbott Laboratories), Principal at Bristol Myers Squibb Co., Principal at Pfizer Inc. and President at Sugen, Inc. (a subsidiary of Pfizer Inc.), Senior Vice President for Global Nutritionals, Inc. and Executive Vice President at Global Pharmaceuticals Cos LLC.
He received an MBA and an undergraduate degree from Indiana University. |
| Henry A. McKinnell |
Henry A. McKinnell is a businessperson who has been at the head of 9 different companies is Member of Massachusetts Institute of Technology and on the board of 15 other companies.
Dr. McKinnell previously occupied the position of Director at Moody's Corp., Chairman & Chief Executive Officer for Pfizer Inc. and President of Pfizer Pharmaceuticals, Inc. (a subsidiary of Pfizer Inc.), Director at EMI Holding, Inc., Chairman & Chief Executive Officer at Optimer Pharmaceuticals LLC, Chairman of Health Industry Manufacturers Association and Co-Chairman at Accordia Global Health Foundation.
Dr. McKinnell received an undergraduate degree from the University of British Columbia and a doctorate and an MBA from Stanford Graduate School of Business. |
| Joseph M. Feczko |
Presently, Joseph M. Feczko occupies the position of Chairman at Cardoz Pharmaceuticals AB. He is also Member-Pharmaceutical Drug Forum at National Academy of Medicine (United States) and Director-Trachoma Technical Expert Committee at The Task Force for Global Health, Inc. and on the board of 7 other companies.
Dr. Feczko previously held the position of Chief Medical Officer & Senior Vice President at Pfizer Inc. and Director-Clinical Development & Operations at Pfizer Ltd. (a subsidiary of Pfizer Inc.), Medical Director-Research & Development at GlaxoSmithKline Plc and Director-Technology Strategy Board at United Kingdom Department for Business, Innovation & Skills.
Joseph M. Feczko received an undergraduate degree from Loyola University of Chicago and a doctorate from the University of Illinois College of Medicine. |
